Microsoft, Adaptive Biotechnologies launch virtual COVID-19 immunity study: 4 details

Microsoft partnered with Adaptive Biotechnologies to launch an initiative to map and measure immune response to the COVID-19 virus in an effort to improve diagnostics and accelerate reliable testing.

Four things to know:

1. The partners are enrolling participants in a virtual clinical study called ImmuneRACE. The effort aims to collect data from 1,000 individuals in U.S. metropolitan areas most affected by COVID-19. LabCorp will manage the collection of blood samples and nose and throat swabs from participants through the Covance drug development business.

2. The partners will make the de-identified patient information available to public health officials, academia and industry to accelerate treatment for the virus.

3. Adaptive and Microsoft are developing an alternative diagnostic test for individuals with known exposure or symptoms as well as efforts to triage patients and deliver treatment based on risk. It also aims to further ongoing immunity surveillance testing of populations.

4. In the study, Adaptive and Microsoft will measure the presence of T cells in the immune system for early disease identification and to combat infection.

More articles on health IT:
The IT projects 12 health system execs will put on hold due to the pandemic
Mount Sinai, Google Nest partner for COVID-19 patient monitoring
Many COVID-19 contact tracers aren't reporting in real time



© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Whitepapers

Featured Webinars